Documents for the 2nd EURORDIS Mulit-stakeholder Symposium
Useful reading
EURORDIS Pre-Symposium webinar February 2017
-
Using the one-text process, Charles Barker, PrimeMovers, 2017
-
Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)
-
Principles for Collaborative, Mutually Acceptable Drug Pricing; Conclusions of the PharmaDiplomacy Dialogue; Meteos
-
BEUC Position on access to medicines, The European Consumer Organisation
-
Statement: civil Society urges Member States to defend the need for a critical review of the intellectual property system and incentives for medical innovation
-
Statement: civil society urges Member States to support the Dutch EU Presidency’s vision on access to affordable medicines
-
Open letter to the European Commission on the follow-up of the June 2016 EU Council Conclusions on “Strengthening the Balance in the Pharmaceutical Systems in the EU and its Member States”
-
Core Principles from the Patients’ Perspective on the Value and Pricing of Innovative Medicines; European Patients’ Forum
-
Future scenarios about drug development and drug pricing; KCE reports, Belgian Healthcare Knowledge Centre
-
Report of the United Nations Secretary-General’s High-Level Panel on Access to Medicines, Promoting innovation and access to medicines
-
Le prix de la vie: le prix indécent des medicaments, ça va durer encore longtemps?Médecins du Monde campaign
-
EUCERD core recommendations on rare disease patient registration and data collection
-
European Reference Networks, European Commission webpage
-
European Reference Networks, RD-Action webpage
-
Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European, countries; 2013; Orphanet Journal of Rare Diseases
-
Generating Health Technology Assessment Evidence for Rare Diseases; 2014; International Journal of Technology Assessment in Health Care
-
Sustainable rare diseases business and drug access: no time for misconceptions; 2013; Orphanet Journal of Rare Diseases
-
The orphan drug pipeline in Europe; 2016; BioBusiness Briefs
-
Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries; 2015; PLOS ONE
-
Orphan drugs: the regulatory environment; 2013; Drug Discovery Today
-
Principles for consistent value assessment and sustainable funding of orphan drugs in Europe; 2015; Orphanet Journal of Rare Diseases
During the symposium
Page created: 21/02/2017
Page last updated: 20/03/2017